CTOs on the Move

64x Bio

www.64xbio.com

 
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.64xbio.com
  • 409 Illinois Street
    San Francisco, CA USA 94158
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Healthnet Solutions

Healthnet Solutions is a Bloomfield Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iBio

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio`s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It`s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.

ABS Global

Headquartered in DeForest, Wisconsin, ABS Global is the world-leading provider of bovine genetics, reproduction`services, technologies and uddercare products.

Planetrx Com

Planetrx Com is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenxbio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.